2017 ANNUAL MEETING

Immune Deficiency & Dysregulation North American Conference
March 23-26, 2017 • The Westin Seattle • Seattle, Washington
ABOUT CIS
The Clinical Immunology Society (CIS), established in 1986, is the key interdisciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. CIS is an international professional organization which includes more than 900 clinicians, investigators, and trainees.

The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders.

The primary objectives and purposes of CIS are to:
- facilitate the interchange of ideas and information among physicians and other investigators who are concerned with immunological/inflammatory diseases;
- promote research on the causes and mechanisms of diseases relating to the immune system and, as a result, to unify concepts of disease pathogenesis;
- encourage investigators and clinicians to share in their knowledge of immunologically active drugs and other interventions;
- promote application and dissemination of recent advances in biomedical science for the prevention, diagnosis and treatment of diseases related to immunity and inflammation; and
- foster excellence in research and medical practice.

CIS NATIONAL OFFICE
555 East Wells Street, Suite 1100
Milwaukee, WI 53202
Phone: 414.224.8095
E-mail: info@clinimmsoc.org
www.clinimmsoc.org

2017 ANNUAL MEETING PROGRAM COMMITTEE
CO-CHAIRS:
Jordan S. Orange, MD, PhD
Baylor College of Medicine
Houston, TX

Roshini Sarah Abraham, PhD
Mayo Clinic
Rochester, MN

COMMITTEE:
Steven M. Holland, MD
NIAID, NIH
Bethesda, MD

Sergio Rosenzweig, MD, PhD
NIAID, NIH
Bethesda, MD

Kathleen E. Sullivan, MD, PhD
Children's Hospital of Philadelphia
Philadelphia, PA

Troy R. Torgerson, MD, PhD
University of Washington
Seattle, WA

TABLE OF CONTENTS
About CIS ................................................................. 1
General Meeting Information ................................. 3
Continuing Medical Education Information .......... 4
Speakers Disclosures ............................................. 5
Seattle Visitor Information .................................. 6
Schedule At-A-Glance .......................................... 7
Schedule of Events .............................................. 8
Exhibit Hall Floor Plan ....................................... 15
Exhibitor Listing .................................................. 17
Poster Listing ...................................................... 18
2017 Annual Meeting Supporters ......................... 24

CONNECT WITH YOUR COLLEAGUES!
“LIKE” CIS on Facebook
Follow us on Twitter @CLINIMMSOC #CIS2017 #CISinSeattle
Join our Group on LinkedIn

CIS-0217-129
Dear Colleagues,


CIS is the key inter-disciplinary organization for the field of clinical immunology and is devoted to fostering developments in the science and practice of clinical immunology. The mission of CIS is to facilitate education, translational research and novel approaches to therapy in clinical immunology and to promote excellence in the care of patients with immunologic/inflammatory disorders.

The CIS leadership and the members of the Program Committee have jointly defined our goals and have engaged clinicians and researchers from all types of backgrounds to try to identify the best manner of addressing the critical needs. The primary goal of the Annual Meeting is to provide an exciting venue for the presentation of the newest immune deficiency diseases and the pathogenesis of these defects in molecular terms. The substance of the conference will be cutting edge clinical and basic science research. Another goal is to educate clinicians regarding state of the art clinical care. We recognize that physicians in training who are likely to see these patients need sessions on the pragmatic aspects of diagnosis and clinical care; thus sessions were designed to provide a stimulating discussion of these issues, while delving into unsolved questions. The final major goal of this conference is to begin to grow the community of physicians who feel competent to see patients with primary immune deficiency. We believe that this is the only way to consolidate and build up a community of physicians and scientists who are working in this area. This Annual Meeting is sure to foster enthusiasm and provide advanced training for physicians and researchers working in the field of primary immune deficiency.

The CIS leadership is excited about the 2017 Annual Meeting and we look forward to bringing accomplished clinical researchers together to present what is sure to be outstanding science. We hope you enjoy the meeting!

Regards,

Jordan S. Orange, MD, PhD  
Baylor College of Medicine  
Houston, TX  
2017 Program Committee Co-Chair

Roshini Sarah Abraham, PhD  
Mayo Clinic  
Rochester, MN  
2017 Program Committee Co-Chair
Submit a Manuscript

The *Journal of Clinical Immunology* accepts manuscripts in the areas of human, basic, and clinical immunology and molecular biology. The areas of basic immunology include (but are not limited to) studies of lymphocytes, antigen presenting cells, neutrophils, natural killer cells, complement components, immunoglobulins, antibodies, cytokines and their receptors, immunoregulation, signal transduction, T−cell receptors, and immunoglobulin genes. Papers on animal models of human diseases are welcome. Articles dealing with molecular biology related to human diseases are accepted. Special Articles are by invitation only. Case reports will only be considered if they are linked to novel new findings/science or are accompanied by an extensive review of the relevant medical literature to the findings of the case report.

Authors, editors and reviewers of *Journal of Clinical Immunology* use our fully web-enabled online manuscript submission and review system. To keep the review time as short as possible, we request authors to submit manuscripts online to the journal’s editorial office. Our online manuscript submission and review system offers authors the option to track the progress of the review process of manuscripts in real time.

To submit a manuscript, please visit http://www.editorialmanager.com/joci/
MEETING LOCATION

All educational sessions, posters, exhibits, and registration held as part of the CIS Annual Meeting will take place at the The Westin Seattle.

The Westin Seattle
1900 5th Avenue
Seattle, WA, 98101
P: 206-728-1000

Exhibit Hall
The Westin Seattle ~ Grand Ballroom II and III
Exhibitors provide the latest information on products and services available to physicians, researchers and allied health professionals in the field of immunology. Take this valuable opportunity to meet with companies and organizations specializing in all areas of the immunology field.

Exhibitor Move-In
Thursday March 23
8:00am – 5:00pm

Exhibit Hours
Friday, March 24th
12:30pm – 2:00pm & 6:00pm – 7:00pm
Saturday, March 25th
12:30pm – 2:00pm & 5:00pm – 7:00pm

Exhibitor Move-Out
Saturday, March 25th
7:00pm – 10:00pm

POSTER SESSIONS
Poster sessions are held in the Grand Ballroom II and III, and authors will be present with their posters from 1:30pm to 2:00pm Friday, March 24 and Saturday, March 25. Lunch will be available in the Grand Foyer during the exhibit hall opening and poster session hours.

PUBLISHING OF ABSTRACTS
The abstracts submitted to the 2017 Annual Meeting are published in the April issue of Journal of Clinical Immunology, the official journal of the Clinical Immunology Society. Copies are available at the CIS registration desk.

ACCESSIBILITY
If you require special arrangements in order to fully participate in the CIS Annual Meeting, please speak with a CIS staff member at the registration desk.

NAME BADGES
All registered attendees at the CIS Annual Meeting will receive a name badge as part of their registration packet. These badges should be worn at all times as they will be used to control access to sessions and activities.

SMOKING
Smoking is prohibited at all CIS Annual Meeting sessions and events.

EVALUATIONS
Delegates will have the opportunity to provide feedback on their experience at the 2017 CIS Annual Meeting. After the meeting all registered delegates will receive an online evaluation to complete. Evaluations are an important part in helping us to improve our educational sessions so please take a moment to complete it!

LISTSERV
CIS-PIDD LIST SERVICE & ECI LIST SERVICE
The E-mail CIS-PIDD service has been set up to provide an easy way for CIS members to discuss issues of common interest. The E-mail ECI List Service has been set up to provide fellows and junior faculty a dedicated place to discuss issues with each other; it is limited to Fellows-in-Training, Junior Faculty and a few select Senior Faculty members for mentor purposes. The server group may also be used to look for collaborators or new faculty members. These List Services are set up as a communication tool to help you interact with your colleagues. It is closed to the general public. Visit www.clinimmsoc.org to sign up.
PURPOSE
Provide an opportunity for physicians to receive updated information and solidify their knowledge of primary immune deficiency.

CONTENT AREA
The content will cover practical, cutting edge and theoretical issues related to patient care. The majority of the immune deficiencies will be covered to provide the maximal educational experience.

TARGET AUDIENCE
Physicians, scientists and nurses who are involved in the evaluation and/or care of patients with primary immune deficiencies. Participants should be pediatricians, internists, or scientists committed to the clinical management of patients with primary immunodeficiency diseases. These candidates may have backgrounds in immunology, adult medicine, rheumatology, hematology, laboratory immunology, or allergy/immunology.

LEARNING OBJECTIVES
At the completion of the activity, participants should be able to:
• Recognize the value of new research techniques;
• Describe new research findings in immunology;
• Explain the diagnosis and management of diseases and disorders across various subspecialties of medicine.

ACCME ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the Clinical Immunology Society (CIS). The CIS is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT
The Clinical Immunology Society designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CLAIMING CME
To claim CME credit and print out your CME certificate and/or certificate of attendance, please visit http://www.clinimmsoc.org/cme/am17/.
DISCLOSURES OF CONFLICT OF INTEREST

2017 ANNUAL MEETING PROGRAM COMMITTEE AND SPEAKER DISCLOSURES
The Clinical Immunology Society (CIS) require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved. The existence or absence of COI for everyone in a position to control content appears below.

Andrew Cant, MD
GREAT NORTH CHILDREN’S HOSPITAL
Sanofi Pasteur MSD – Consultant receiving consulting fee

Charlotte Cunningham-Rundles, MD, PhD
MOUNT SINAI MEDICAL CENTER
Momental – Consultant receiving consulting fee
Biotest – Consultant receiving consulting fee
ADMA – Consultant receiving consulting fee

Chris Wilson, MD
Venrock - Consultant receiving consulting fee
Avalon Ventures - Consultant receiving consulting fee

Daniel Campbell, PhD
BENAROYA RESEARCH INSTITUTE
No Disclosure Received

Elie Haddad, MD, PhD
CHU SAINTE-JUSTINE, UNIVERSITY OF MONTRÉAL
CSL Behring - Investigator Initiated Grant - Principal Investigator
Sigma-Tau - Consultant receiving consulting fee

Isabelle Meyts, MD, PhD
UNIVERSITY HOSPITALS LEUVEN
CSL-Behring – Honoraria for speaking and teaching; Research grant recipient
Steripolar - Honoraria for speaking and teaching
Baxalta/Shire - Research Grant Recipient

Jared Silver, MD, PhD
BRIGHAM AND WOMEN’S HOSPITAL AND HARVARD MEDICAL SCHOOL
Grifols – Research Grant Recipient

Jean-Laurent Casanova, MD, PhD
THE ROCKEFELLER UNIVERSITY
Novacor - Consultant receiving consulting fee
ADMA – Membership on advisory committee or review committee; Consultant receiving consulting fee
Nimbus - Independent contractor receiving consulting fee
Vitae Pharmaceuticals, Inc - Independent contractor receiving consulting fee

Jordan Orange, MD, PhD
BAYLOR COLLEGE OF MEDICINE
ADMA - Membership on Advisory Committee or Review Committee; Consultant receiving honoraria
CSL Behring - Consultant receiving honoraria
Shire - Consultant receiving honoraria
Grifols - Consultant receiving consulting fee

Lauri Burroughs, MD
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Medac GmB–Provides Treosulin for study and funds to help run clinical trial

Lennart Hammarström, MD, PhD
KAROLINSKA INSTITUTET
Beijing Genomics - Consultant receiving consulting fee
Mabtech Diagnostics – Stock purchased – Scientific Advisor

Lori Broderick, MD, PhD
UNIVERSITY OF CALIFORNIA, SAN DIEGO
NIH - Research grant recipient

Manish Butte, MD, PhD
UCLA MEDICAL CENTER
Allertope, Inc. – Co-founder with no operational role receiving ownership interests
Microrevolution, LLC - Co-founder with no operational role ownership interests
Alpine Immune Sciences – Scientific Advisory Board with no operational role receiving ownership interests
EpikBio - Co-founder with no operational role receiving ownership interests
Chimera Bio - Scientific Advisory Board with no operational role receiving ownership interests

Markus Seidel, MD
MEDICAL UNIVERSITY OF GRAZ
Baxalta/Shire – Speaking and Teaching; Membership on advisory committee or review committee with honoraria
Novartis – Speaking and Teaching; Membership on advisory committee or review committee with honoraria

Michael Jensen, MD
SEATTLE CHILDRENS’ RESEARCH INSTITUTE
Juno Therapeutics, Inc. – Consultant receiving consulting fee; Membership on advisory committee or review committee receiving Intellectual property rights and ownership interest

Mikko Seppänen, MD, PhD
HELSDINK UNIVERSITY HOSPITAL
CSL Behring - Speaking and Teaching receiving honoraria
Octapharma - Speaking and Teaching receiving honoraria

Monica Lawrence, MD
UNIVERSITY OF VIRGINIA
Merck – Member of clinical trial events adjudication committee receiving consulting fee
Pharmacosmos - Member of clinical trial events adjudication committee receiving consulting fee

Ricardo Sorensen, MD
LSU HEALTH SCIENCES CENTER
CSL Behring - Speaker fee for speaking
Shire/Baxalta - Investigator initiated research project support

Stuart Tangye, PhD
UNIVERSITY OF NSW, AUSTRALIA
Jeffrey Modell Foundation - Research grant recipient
Cancer Council NSW - Research grant recipient
National Health and Medical Research Council, Australia - Research grant recipi ent

Roshini Abraham, PhD
MAYO CLINIC
Baxalta/Shire - Consultant receiving consulting fee

Troy Torgerson, MD, PhD
UNIVERSITY OF WASHINGTON AND SEATTLE CHILDREN’S RESEARCH INSTITUTE
Baxalta/Shire - Consultant receiving consulting fee
CSL Behring - Consultant receiving consulting fee
ADMA - Consultant receiving consulting fee

aTyr Pharmaceuticals – Consultant receiving consulting fee

V. Koneti Rao, MD
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH
Novartis - Funds through CRADA - Sponsor of research project

Vincent Bonagura, MD
ALEXANDRA & STEVEN COHEN CHILDRENS’ MEDICAL CENTER
Baxalta/Shire – Advisory committee member receiving speaker fee
Grifols – Advisory committee member receiving speaker fee
SEATTLE VISITOR INFORMATION

THINGS TO DO:

**Pike Place Market:** 110 year old farmers market with 35 restaurants, 11 bakeries, fish & produce vendors. Visit the gum wall and the fish stand where they throw the fish while you're there!

**Seattle Center:** This 74-acre park was originally built for the 1962 World’s Fair. It now serves as a location for arts, entertainment & leisure activities. Visit the iconic Space Needle, the Museum of Pop, the Pacific Science Center and more!

**Pioneer Square:** Home of the great fire of 1889, and the birth place of UPS, THE UNDERGROUND TOUR, many art & glass galleries & our professional sports stadiums.

**Waterfront & Piers:** Catch spectacular views of Elliott Bay, eat at one of the many fresh seafood restaurants, buy all your Seattle souvenirs at one of the many souvenir & curio shops, take a scenic ferry ride or visit the Seattle aquarium, all available on the Seattle waterfront.

**International district (A.K.A., CHINA TOWN):** It isn’t just a place to shop & play; it’s a thriving community & neighborhood. Uwajimaya Asian groceries & gifts. Hing Hay Park, Wing Luke museum, the pinball machine museum, are just some of the many attractions here.

**Discovery Park:** A 534 acre park in the peninsular neighborhood Magnolia. 12 miles of walking trails, the United Indians of All Tribes Daybreak Cultural Center, a lighthouse, and the chance to view Pacific Northwest wildlife.

**Ballard:** A hip little town in the NW Seattle area settled in 1853...offering some of the best restaurants, pubs, shops, spas & parks. Shop & stroll Market St while you’re there.

**Volunteer Park:** Located in the North Capitol Hill neighborhood, this densely populated residential district features a prominent nightlife & entertainment area. Many great restaurants and a large alternative & counter culture community exist here.

**Bainbridge Island:** Has Island charm, natural beauty, rural character, offering many parks and artisan wineries, unique stores & restaurants.

PLACES TO EAT

**Relish Burger Bistro** (Located in The Westin)
American
Open for breakfast, lunch, and dinner
Relish Burger Bistro is a contemporary restaurant offering a modern twist on an American classic, combining Seattle’s culinary influence with gourmet burgers at downtown Seattle’s newest eatery.

**Barolo (0.05 mi)**
Italian
Open for lunch and dinner
Barolo Ristorante offers a mix of timeless, old-world northern Italian dishes crafted with a contemporary presentation, using quality natural and organic products and ingredients, many from the Pacific Northwest.

**Andaluca (0.07 mi)**
Mediterranean
Open for breakfast and dinner
Andaluca is a nationally recognized culinary oasis. Resonating with the romance of the Mediterranean, its food and design have been a winning combination since 1996.

**Assaggio (0.09 mi)**
Italian
Open for lunch and dinner
Italian cuisine in a space filled with Michelangelo-inspired artwork.

**Miller’s Guild (0.09 mi)**
American
Open for breakfast, lunch, and dinner
Wood-fired New American fare & cask-aged cocktails in sleek, modern digs.

**Dahlia Lounge (0.1 mi)**
Northwest
Open lunch and dinner
Modern space serving Asian-infused Pacific Northwest cuisine & known for its coconut cream pie.

**Le Pichet (0.3 mi)**
French
Open for brunch, lunch & dinner
Le Pichet is a 32 seat restaurant specializing in the regional cuisine and wine of France.
# 2017 CIS Annual Meeting Schedule At-A-Glance

## Thursday, March 23

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30pm – 6:00pm</td>
<td>Welcome from CIS President &amp; Fellowship Awardee Presentations</td>
<td>Grand 1</td>
</tr>
</tbody>
</table>
| 6:00pm – 7:00pm | Robert A. Good Lecture  
Newborn Screening for PID – and Beyond  
*Lennart Hammarström, MD, PhD* | Grand 1    |

## Friday, March 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am – 9:30am</td>
<td>Plenary Session: Next Generation Genomics in This Generation</td>
<td>Grand 1</td>
</tr>
<tr>
<td>9:30am – 10:00am</td>
<td>Morning Break</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>10:00am – 11:00am</td>
<td>Guided Poster Sessions</td>
<td>Vashon I &amp; II</td>
</tr>
<tr>
<td>11:00am – 12:30pm</td>
<td>Plenary Session: Immunological Lessons Learned from PIDs</td>
<td>Grand 1</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Lunch / Exhibit Hall Open</td>
<td>Grand 2 &amp; 3 Foyer</td>
</tr>
<tr>
<td>1:30pm – 2:00pm</td>
<td>Poster Presentation Viewing / Exhibit Hall Open</td>
<td>Grand 2 &amp; 3</td>
</tr>
<tr>
<td>2:00pm – 3:30pm</td>
<td>Plenary Session: The “Ome” and “Omics”</td>
<td>Grand 1</td>
</tr>
<tr>
<td>3:30pm – 4:00pm</td>
<td>Coffee Break</td>
<td>Grand Foyer</td>
</tr>
</tbody>
</table>
| 4:00pm – 5:00pm | The CIS Fahey/Rose Founders Lecture  
Translating Immunological Advances Into Solutions for Global Health Problems  
*Chris Wilson, MD* | Grand 1    |
| 5:00pm – 5:30pm | DAIT/NIAID Funding Opportunities for PID                           | Grand 1    |
| 5:30pm – 6:00pm | CIS Business Meeting & Award Presentations Wine & Cheese Reception to Follow | Grand 1    |
| 6:00pm – 7:30pm | ECI Reception                                                       | Lobby Bar Loft|

## Saturday, March 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am – 9:30am</td>
<td>Plenary Session: Immune Regulation</td>
<td>Grand 1</td>
</tr>
<tr>
<td>9:30am – 10:00am</td>
<td>Coffee Break</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>10:00am – 11:00am</td>
<td>Guided Poster Sessions</td>
<td>Vashon I &amp; II</td>
</tr>
<tr>
<td>11:00am – 12:30pm</td>
<td>Plenary Session: Hematopoietic Cell Transplantation and Immune Reconstitution</td>
<td>Grand 1</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Lunch / Exhibit Hall Open</td>
<td>Grand 2 &amp; 3 Foyer</td>
</tr>
<tr>
<td>1:30pm – 2:00pm</td>
<td>Poster Presentation Viewing / Exhibit Hall Open</td>
<td>Grand 2 &amp; 3</td>
</tr>
<tr>
<td>2:00pm – 3:30pm</td>
<td>Plenary Session: Tales From the Listserv</td>
<td>Grand 1</td>
</tr>
<tr>
<td>3:30pm – 4:00pm</td>
<td>Coffee Break</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>4:00pm - 4:20pm</td>
<td>Presidential Award Lecture</td>
<td>Grand 1</td>
</tr>
</tbody>
</table>
| 4:20pm – 5:00pm | Richard Schiff Lecture  
Combinatorial Approaches to Understand Autoimmune Risk:  
Mechanistic Insight from Immunodeficiency and GWAS  
*David Rawlings, MD* | Grand 1    |
| 5:00pm – 7:00pm | CIS Closing Reception                                               | Grand 2 & 3|

## Sunday, March 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am – 10:00am</td>
<td>Plenary Session: Hot New Defects in Primary Immunodeficiencies!</td>
<td>Grand 1</td>
</tr>
<tr>
<td>10:00am – 10:15am</td>
<td>Coffee Break</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>10:15am – 12:15pm</td>
<td>Plenary Session: Clinical Management Conundrums in PIDs</td>
<td>Grand 1</td>
</tr>
</tbody>
</table>
# SCHEDULE OF EVENTS

## THURSDAY, MARCH 23

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 4:30 pm - 4:40 pm | Welcome from CIS President  
Jordan Orange, MD, PhD  
Baylor College of Medicine & Texas Children's Hospital | Grand Ballroom I          |
| 4:40 pm – 6:00 pm | **CIS Fellowship Grantee Presentations**  
1.5 AMA PRA Category 1 Credits™  
Moderator:  
Jordan Orange, MD, PhD, Baylor College of Medicine  
Speakers:  
Revealing the Role of Human IgA in Gut Homeostasis  
Jared Silver, MD, PhD, Brigham and Women's Hospital  
Using Persistent Cutaneous Viral Infections to Uncover Novel Immune Dysfunction  
Sarah Henrickson, MD, PhD, The Children's Hospital of Philadelphia  
Oral Abstract  
SUCCESSFUL CLINICAL STUDY OF LENIOLISIB (CDZ173), A SMALL MOLECULE PI3K-DELTA INHIBITOR, IN PATIENTS WITH APDS/PASLI  
V. Koneti Rao, MD, National Institute of Allergy and Infectious Diseases, NIH | Grand Ballroom I          |
| 6:00pm - 7:00pm  | **Robert A. Good Lecture**  
Sponsored by The Robert A. Good Society and The Jeffrey Modell Foundation  
1 AMA PRA Category 1 Credits™  
Moderator:  
Jordan Orange, MD, PhD, Baylor College of Medicine  
Speaker:  
Newborn screening for PID - and Beyond  
Lennart Hammarström, MD, PhD, Karolinska Institutet | Grand Ballroom I          |
| 7:00pm - 8:30pm  | **Corporate Sponsored Dinner Symposium**  
Navigating through the Diagnostic and Treatment Controversies in Specific Antibody Deficiency:  
US and European Perspectives and Recommendations  
*Ticketed Event*  
Sponsored by an Unrestricted Educational Grant from Shire | Fifth Avenue Room         |

## FRIDAY, MARCH 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td><strong>Continental Breakfast</strong></td>
<td>Grand Foyer</td>
</tr>
</tbody>
</table>
| 8:00am - 9:30am | **Plenary Session: Next Generation Genomics in This Generation**  
1.5 AMA PRA Category 1 Credits™  
Moderators:  
Roshini Sarah Abraham, PhD, Mayo Clinic  
Yuval Itan, PhD, The Rockefeller University  
Speakers:  
Technologies Around Genomics  
Brendan Lee, MD, PhD, Baylor College of Medicine  
Understanding the Shared Genetic Architecture of Autoimmune and Inflammatory Disorders: Implications on Mechanism and Clinical Translation  
Charlly Kao, PhD, Children's Hospital of Philadelphia  
21st Century Genomic Advances for Clinicians  
Isabelle Meyts, MD, PhD, University Hospitals Leuven  
Oral Abstract  
NUCLEASE-TARGETED GENE-EDITING TO ACHIEVE STABLE FOXP3 EXPRESSION IN PRIMARY HUMAN T CELLS DELAYS THE ONSET XENOGENIC MODEL OF GRAFT-VERSUS-HOST DISEASE (GVHD)  
Yufei Xiang, MD, PhD, Seattle Children's Research Institute | Grand Ballroom I          |
| 9:30am - 10:00am | **Morning Break**                                                      | Grand Foyer               |
### FRIDAY, MARCH 24, CONTINUED

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
<th>Location</th>
</tr>
</thead>
</table>
| 10:00am - 11:00am | **Guided Poster Session Group I**  
Moderators:  
Jolan Walter, MD, PhD, Johns Hopkins All Children's Hospital  
Artemio Jongco, MPH, MD, PhD, Feinstein Institute for Medical Research  
Huie Jing, PhD, National Institute of Allergy and Infectious Diseases, NIH  
Troy R. Torgerson, MD, PhD, Seattle Children's Research Institute  
Isabelle Meyts, MD, PhD, University Hospitals Leuven  
Amanda K. Urban, CRNP, Leidos Biomedical Research  
Tareian A. Cazares, MS, Cincinnati Children's Hospital Medical Center | Vashon I |
| 10:00am - 11:00am | **Guided Poster Session Group II**  
Moderators:  
Lisa Kobrynski, MD, MPH, Emory University  
Jennifer Leiding, MD, University of South Florida  
Stefano Volpi, MD, PhD, Istituto Giannina Gaslini  
Rachel Sparks, MD, MPH, National Institute of Allergy and Infectious Diseases, NIH  
Sung-Yun Pai, MD, Boston Children's Hospital  
Amanda K. Urban, CRNP, Leidos Biomedical Research  
Roxane Labrosse, MD, CHU Sainte-Justine, University of Montreal  
Saul Oswaldo Lugo-Reyes, MD, MS, National Institute of Pediatrics | Vashon II |
### SCHEDULE OF EVENTS

**FRIDAY, MARCH 24, CONTINUED**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 11:00am - 12:30pm | **Plenary Session: Immunological Lessons Learned from PIDs**  
1.5 AMA PRA Category 1 Credits™  
Moderators:  
Manish Butte, MD, PhD, UCLA  
Monica Lawrence, MD, University of Virginia  
Speakers:  
B Cell Tolerance Mechanisms and Defects in PIDs  
**Neil Romberg, MD**, University of Pennsylvania  
Conventional T Cell Subsets  
**Stuart Tangye, PhD**, Garvan Institute of Medical Research  
Dendritic Cell Biology  
**Venetia Bigley, MB, BChir, PhD, MRCP, FRCPath**, Newcastle University  
Oral Abstracts  
**MUTATIONS IN THE TYROSINE-PROTEIN KINASE LYN CAUSE AN EARLY-ONSET NEUTROPHILIC VASCULITIS SYNDROME**  
Adriana A. Jesus, MD, PhD, National Institutes of Health  
**MUTATIONS IN THE H+-ATPASE SUBUNIT ATP6V0A2 ASSOCIATED WITH CUTIS LAXA ALSO CAUSE NK CELL DEFICIENCY**  
Levi B. Watkin, PhD, Baylor College of Medicine | Grand Ballroom I |
| 12:30pm - 1:30pm | Lunch / Exhibit Hall Open                                                                  | Grand Ballroom II & III, Foyer |
| 1:30pm - 2:00pm | Poster Presentation Viewing / Exhibit Hall Open                                             | Grand Ballroom II & III |
| 2:00pm - 3:30pm | **Plenary Session: The “Ome” and “Omics”**  
1.5 AMA PRA Category 1 Credits™  
Moderators:  
**Sergio Rosenzweig, MD, PhD**, National Institute of Allergy and Infectious Diseases, NIH  
**Elena Hsieh, MD**, University of Colorado, Denver  
Speakers:  
Systems Genomics and Systems Immunology  
**John Tsang, PhD**, National Institute of Allergy and Infectious Diseases, NIH  
Transcriptome of Human Treg Subsets  
**Daniel Campell, PhD**, Benaroya Research Institute  
A New Genetic Etiology of Inherited NK Cell Deficiency  
**Emmanuelle Jouanguy, PhD, INSERM / Université Paris Descartes**  
Oral Abstract:  
**DRIED BLOOD SPOTS FOR GENE SEQUENCING: TRAVELLING ON LOW BUDGET!**  
Gesmar Segundo, MD, PhD, Seattle Children’s Research Institute, Federal University of Uberlandia | Grand Ballroom I |
| 3:30pm - 4:00pm | Afternoon Break                                                                            | Grand Foyer |
| 4:00pm - 5:00pm | **The CIS Fahey/Rose Founders Lecture**  
1 AMA PRA Category 1 Credits™  
Moderators:  
Joyce Yu, MD, Morgan Stanley Children’s Hospital/Columbia University Medical Center  
**Hans Ochs, MD**, University of Washington  
Speaker:  
Translating Immunological Advances Into Solutions for Global Health Problems  
Christopher Wilson, MD | Grand Ballroom I |
| 5:00pm - 5:30pm | **Plenary Session: DAIT/NIAID Funding Opportunities for PID**  
.5 AMA PRA Category 1 Credits™  
**Frosso Voulgaropoulou, PhD**, National Institute of Allergy and Infectious Diseases, NIH | Grand Ballroom I |
| 5:30pm - 6:00pm | **CIS Business Meeting & Award Presentations**  
Wine & Cheese Reception to Follow | Grand Ballroom I |
<p>| 6:00pm – 7:30pm | <strong>Early Career Immunologists (ECI) Reception</strong> | Lobby Bar Loft |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td><strong>Continental Breakfast</strong></td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>8:00am - 9:30am</td>
<td><strong>Plenary Session: Immune Regulation</strong></td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td></td>
<td>1.5 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thomas Fleisher, MD, NIH Clinical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joud Hajjar, MD, Baylor College of Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Formation of Immunological Memory in Complex Infections</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marion Pepper, PhD, University of Washington</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Deficiency of Adenosine Deaminase 2—A Master of Disguise</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amanda Ombrello, MD, NIHGRI, NIH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Manipulating Regulatory T Cells to Restore Tolerance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Talal Chatila, MD, Boston's Children Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Abstracts</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VERY EARLY ONSET IBD- THE SEARCH FOR MONOGENIC CAUSES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kathleen Sullivan, MD, PhD, Children's Hospital of Philadelphia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AN INHERITED SYNDROME OF AUTOIMMUNITY ASSOCIATED WITH CD40LG DUPLICATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carole Le Coz, PhD, Children's Hospital of Philadelphia</td>
<td></td>
</tr>
<tr>
<td>9:30am - 10:00am</td>
<td><strong>Morning Break</strong></td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>10:00am – 11:00am</td>
<td><strong>Guided Poster Session Group I</strong></td>
<td>Vashon I</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jack Bleesing, MD, PhD, Cincinnati Children's Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zeynep Yesim Kucuk, MD, Cincinnati Children's Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LIVER ABNORMALITIES IN DOCK8 DEFICIENCY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anahita Agharahimi, CRNP, National Institute of Allergy and Infectious Diseases, NIH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HUMAN CD40L DEFICIENCY DYSREGULATES THE MACROPHAGE TRANSCRIPTOME CAUSING FUNCTIONAL DEFECTS THAT ARE IMPROVED BY EXOGENOUS IFN-γ</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antonio Condino-Neto, MD, PhD, University of Sao Paulo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH XIAP DEFICIENCY HAVE CIRCULATING FREE IL-18 WHICH MAY REPRESENT A THERAPEUTIC TARGET</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rebecca Marsh, MD, Cincinnati Children's Hospital Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>REDUCED TOXICITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH BUSULFAN, FLUDARABINE AND ALEMTUZUMAB: A PROMISING APPROACH FOR PRIMARY IMMUNE DEFICIENCIES REQUIRING MYELOABLATIVE HCT?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sharat Chandra, MD, MRCPPH, Cincinnati Children's Hospital Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHROMIUM RELEASE NATURAL KILLER CELL CYTOTOXICITY HAS POOR DIAGNOSTIC ACCURACY COMPARED TO FLOW CYTOMETRIC PERFORIN AND CD107a TESTING FOR DETECTION OF PATIENTS WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tamar S. Rubin, MD, University of Alberta</td>
<td></td>
</tr>
</tbody>
</table>
10:00am – 11:00am
Guided Poster Session Group II
Moderators:
Megan A. Cooper, MD, Washington University in St. Louis
David Hagin, MD, PhD, Tel-Aviv Sourasky Medical Center
VEDOLIZUMAB IN CHRONIC GRANULOMATOUS DISEASE: A SAFE AND PROMISING BRIDGE THERAPY FOR CGD RELATED COLITIS
Christa S. Zerbe, MD, National Institute of Allergy and Infectious Diseases, NIH
GERMLINE HYPOMORPHIC, DOMINANT NEGATIVE CARD11 MUTATIONS IN SEVERE ATOPIC DISEASE.
Andrew L. Snow, PhD, Uniformed Services University of the Health Sciences
SEVERE COMBINED IMMUNODEFICIENCY CAUSED BY THYMIC APLASIA DUE TO FAMILIAL MUTATION IN TBX1
David S. Lindsay, MD, University of South Florida
VILLOUS ATROPHY IS THE HALLMARK OF LONG TERM SURVIVAL IN CHRONIC NOROVIRUS INFECTION
Avni Y. Joshi, MD, MS, Mayo Clinic
ROLE OF GUT MICROBIOTA TO MONITOR IMMUNE DYSREGULATION IN CONGENITAL IMMUNE DYSREGULATION SYNDROMES
Eleonora Gambinieri, MD, University of Florence, Department of Sciences for Woman and Child's Health “Anna Meyer” Children’s Hospital

11:00am - 12:30pm
Plenary Session: Hematopoietic Cell Transplantation and Immune Reconstitution
1.5 AMA PRA Category 1 Credits™
Moderators:
Shanmuganathan Chandrakasan, MD, Emory University School of Medicine, Children's Healthcare of Atlanta
László Maródi, MD, Semmelweis University
Speakers:
New Approaches to Hematopoietic Cell Transplantation
Brenda Sandmaier, MD, Fred Hutchinson Cancer Research Center
Immune Reconstitution in Hematopoietic Cell Transplantation
Jan Storek, MD, PhD, University of Calgary
Hematopoietic Cell Transplantation for PIDs: The Indian Experience
Revathi Raj, MD, Apollo Hospitals
Hematopoietic Transplantation: Thinking Outside the Box
Andrew Cant, BSc, MD, FRCP, FRCPCH
Newcastle General Hospital
Oral Abstract
WISKOTT-ALDRICH SYNDROME: AN INTERNATIONAL STUDY ANALYZING THE IMPACT OF TREATMENT DECISIONS ON FREQUENCY OF DISEASE-RELATED COMPLICATIONS AND PHYSICIAN-PERCEIVED QUALITY OF LIFE
Michael H Albert, MD, Dr. von Hauner University Children’s Hospital

12:30pm - 1:30pm
Lunch / Exhibit Hall Open

1:30pm - 2:00pm
Poster Presentation Viewing / Exhibit Hall Open
### Saturday, March 25, Continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 2:00pm - 3:30pm | **Plenary Session: Tales from the Listserv**  
1.5 AMA PRA Category 1 Credits™  
Moderators:  
Elie Haddad, MD, PhD, CHU Ste-Justine, University of Montreal  
Mikko Seppänen, MD, PhD, Helsinki University Central Hospital  
Eric Allenspach, MD, PhD, Seattle Children’s Hospital  
Mystery Case #1  
Megan A. Cooper, MD, Washington University in St. Louis  
Mystery Case #2  
Benjamin Wright, MD, Mayo Clinic  
Mystery Case #3  
Luis Ignacio Gonzalez-Granado, MD, Hospital Universitario Doce de Octubre | Grand Ballroom I          |
| 3:30pm – 4:00pm | Afternoon Break                                                                           | Grand Foyer               |
| 4:00pm – 4:20pm | **Plenary Session: Presidential Award Lecture**  
.25 AMA PRA Category 1 Credits™  
Speaker:  
Charlotte Cunningham-Rundles, MD, PhD, Mt. Sinai Medical School | Grand Ballroom I          |
| 4:20pm - 5:00pm | **Richard Schiff Lecture**  
.75 AMA PRA Category 1 Credits™  
Moderators:  
Antonio Condino-Neto, MD, PhD, University of Sao Paulo  
Andrew L. Snow, PhD, Uniformed Services University of the Health Sciences  
Speaker:  
Combinatorial Approaches to Understand Autoimmune Risk: Mechanistic Insight From Immunodeficiency and GWAS  
David Rawlings, MD, Seattle Children’s Research Institute  
 supported by an unrestricted educational grant from Baxalta | Grand Ballroom I          |
| 5:00pm - 7:00pm | **CIS Closing Reception**                                                                 | Grand Ballroom II & III, |
### SCHEDULE OF EVENTS

**FINAL PROGRAM**  **IMMUNE DEFICIENCY & DYSREGULATION NORTH AMERICAN CONFERENCE**  **MARCH 23-26, 2017  SEATTLE, WASHINGTON**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Continental Breakfast</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>8:00am - 10:00am</td>
<td><strong>Plenary Session: Hot New Defects in Primary Immunodeficiencies</strong>&lt;br&gt;2 AMA PRA Category 1 Credits™&lt;br&gt;Moderators:&lt;br&gt;Maite de la Morena, MD, University of Texas Southwestern&lt;br&gt;Lisa Forbes, MD, Baylor College of Medicine&lt;br&gt;Speakers:&lt;br&gt;A New Syndromic Defect Associated with Thymic Dysfunction and SCID&lt;br&gt;<em>Luigi Notarangelo, MD</em>, National Institute of Allergy and Infectious Diseases, NIH&lt;br&gt;New Genetic NKD&lt;br&gt;<em>Jordan Orange, MD, PhD</em>, Baylor College of Medicine&lt;br&gt;Hoffman Syndrome—New Immunodeficiency Defect&lt;br&gt;<em>Lori Broderick, MD, PhD</em>, University of California, San Diego&lt;br&gt;Human MDAS deficiency confers susceptibility to human rhinovirus infections&lt;br&gt;<em>Helen Su, MD, PhD</em>, National Institute of Allergy and Infectious Diseases, NIH&lt;br&gt;Inherited Human ZNF341 Deficiency Underlies Candidiasis and Allergy&lt;br&gt;<em>Anne Puel, PhD</em>, INSERM/Université Paris Descartes-Sorbonne Paris Cité</td>
<td>Grand Ballroom I</td>
</tr>
<tr>
<td>10:00am - 10:15am</td>
<td>Coffee Break</td>
<td>Grand Foyer</td>
</tr>
<tr>
<td>10:15am - 12:15pm</td>
<td><strong>Plenary Session: Clinical Management Conundrums in PIDs</strong>&lt;br&gt;2 AMA PRA Category 1 Credits™&lt;br&gt;Moderators:&lt;br&gt;Steven Holland, MD, National Institute of Allergy and Infectious Diseases, NIH&lt;br&gt;Nicholas Rider, DO, Texas Children’s Hospital&lt;br&gt;Speakers:&lt;br&gt;Hematopoietic Cell Transplantation for PIDs&lt;br&gt;<em>Lauri Burroughs, MD</em>, Fred Hutchinson Cancer Research Center &amp; University of Washington&lt;br&gt;Autoimmune Cytopenias in PIDs&lt;br&gt;<em>Markus Seidel, MD</em>, Medical University of Graz&lt;br&gt;Cytokine Release Syndrome&lt;br&gt;<em>Michael Jensen, MD</em>, University of Washington School of Medicine &amp; Seattle Children’s Research Institute&lt;br&gt;IBD in PIDs&lt;br&gt;<em>Troy Torgerson, MD, PhD</em>, University of Washington &amp; Seattle Children’s Research Institute&lt;br&gt;Respiratory Papillomatosis&lt;br&gt;<em>Vincent Bonagura, MD</em>, Alexandra &amp; Steven Cohen Children's Medical Center</td>
<td>Grand Ballroom I</td>
</tr>
</tbody>
</table>
EXHIBIT HALL FLOOR PLAN

POSTERS

106
Immunoglobulin National Society

104
Accredo

100
CSL Behring

103
Shire Medical

202
EMED

203
Binding Site

302
Axela Care

303
Beckman Coulter Life Sciences

402
ADMA

301
Novartis

400
Immune Deficiency Foundation

200
Grifols

101
National Jewish Health

300
BPL

406
Shire Commercial

407
Coram

409
Gene Dx

405
Horizon Pharma

403
Kroger

401
Medical College of Wisconsin

ENTRANCE
EXHIBITOR AND SPONSOR DESCRIPTIONS

BOOTH 104  
**Accredo Specialty Pharmacy**  
Accredo is a full-service specialty pharmacy dedicated to caring for people with rare and complex conditions. We deliver specialized pharmacy services and therapy management programs through specialty-trained pharmacists, nurses, reimbursement specialists and patient care representatives. We're committed to proactively supporting patients, their families and providers, and making medicine more affordable.

To learn more about our service, call 866.820.JVIG (4844) or visit accredo.com.

BOOTH 402  
**ADMA Biologics**  
ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize a variety of plasma-based biologics for the proposed treatment of Immune Deficiencies and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons.

ADMA has received U.S. Patent 9,107,906 relating to certain aspects of its product candidate. For more information, please visit www.admabiologics.com.

BOOTH 302  
**Axela Care**  
AxelaCare, a BriovaRx Infusion Services company, is a national home infusion provider with more than 30 pharmacy locations across the country, and an extensive team of employed clinicians. Services include immunoglobulin, anti-infectives, inotropes, parenteral nutrition and other specialty infusions. AxelaCare is a leader in innovation, including our Special Assistance Unit (SAU) for complex clinical and insurance issues, and CareExchange technology for wireless collection of patient outcomes for therapy optimization. Joint Commission and URAC certified, AxelaCare has extensive local, regional, and national payer contracts to facilitate an easy referral process to ensure excellent care for your patients.

BOOTH 303  
**Beckman Coulter Life Sciences**  
Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. More than 275,000 Beckman Coulter systems operate in both Diagnostics and Life Sciences laboratories on seven continents. For over 75 years, our products have been making a difference in peoples' lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. From basic cellular analysis to advanced cell sorting methods and flow cytometry applications count on Beckman Coulter for efficient and reliable solutions to today's research challenges.

BOOTH 203  
**The Binding Site**  
Binding Site is committed to developing special protein assays and automated systems for the improvement of patient care. The market leader in immunodiagnostics for Immunodeficiency, Binding Site assays measure specific antibody response to vaccinations and quantify immunoglobulins, IgG and IgA subclasses. Run on the Optilite® analyzer, the future of special protein testing, our wide menu of assays includes Freelite® for the diagnosis and monitoring of myeloma. With our extensive development expertise, patented antibody production technology, and medical educators, backed by clinical practice guidelines, Binding Site provides healthcare professionals with tools to significantly improve diagnosis and management of patients.  
www.bindingsite.com

BOOTH 300  
**Bio Products**  
Bio Products Laboratory (BPL) is a global company with 60 years of experience in plasma research, technology, and manufacturing. Originally part of the world-famous Lister Institute, BPL has a full line of products derived from plasma collected at 35 company-owned collection centers across the US. For more information please visit www.bpl-us.com.

BOOTH 307  
**Coram CVS Specialty Infusion Services**  
CVS Specialty and Coram provide compassionate, high-quality infusion care to patients where they live, work or travel. With nearly 1,200 skilled clinicians, more than 90 locations and 70 local infusion suites, and more than 30 years of experience, Coram CVS Specialty Infusion Services provides access to 99.9 percent of all infused drugs, including immunoglobulins, and those for alpha-1 and MS.

On-site Clinical Service Liaisons provide complete discharge-to-home coordination. All patients receive individualized care, support, training, and easy-to-use instruction materials. Leading with commitment from the heart, the company has achieved a 96 percent patient satisfaction rating for seven years.

BOOTH 100  
**CSL Behring**  
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients' needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating primary immune deficiencies, coagulation disorders, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world's largest plasma collection networks. For more information visit www.cslbehring.com and follow us on Twitter @CSLBehring.

BOOTH 202  
**EMED Technologies**  
EMED Technologies develops, manufactures and markets the SCIg60™ Infusion System. This unique sub-q infusion system is the only mechanical syringe pump system cleared by FDA for use with subcutaneous immunoglobulin Hizentra, Gammagard and Shire's new Cuvitru. The system features Soft-Glide® needle sets, patented VersaRate® and Versarate Plus® adjustable flow rate control sets and a flow rate calculator which can be accessed at www.versarate.com.

BOOTH 409  
**GeneDX**

BOOTH 200  
**Grifols USA, LLC**  
Grifols is a global healthcare company whose mission is to improve the health and well-being of people around the world. We have three primary divisions – Bioscience, Diagnostic and Hospital – that develop, produce and market our innovative products and services to medical professionals in more than 100 countries around the world.

BOOTH 405  
**Horizon Pharma**  
Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 differentiated and accessible medicines that address unmet medical needs. For more information, please visit: http://www.horizonpharma.com/
**EXHIBITOR LISTING**

**BOOTH 400**

**Immune Deficiency Foundation**
The Immune Deficiency Foundation (IDF) is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.

**BOOTH 106**

**Immunoglobulin National Society**
Immunoglobulin National Society (IgNS) is the leading professional organization dedicated to the advancement of Ig Therapy practice across healthcare professional disciplines, areas of practice, and treatment settings. IgNS offers robust educational programs for nurses, pharmacists, and physicians; Ig Therapy Standards of Practice; and Certification. Visit us at www.ig-an.org. Save the date for the IgNS 6th National Conference on October 5-8, 2017.

**BOOTH 403**

**Kroger Specialty Infusion**
Kroger Specialty Infusion is a specialized provider of IgG therapy. Our unique service model includes pharmacy expertise that includes review and monitoring of patient outcomes and a unique wellness approach to Ig therapy. We possess a national network of infusion nurses specifically trained in IgG administration. Our streamlined care coordination includes superior reimbursement services and a high touch patient advocacy program tailored to the individualized needs of IgG patients and their caregivers.

**BOOTH 201**

**Leadiant Biosciences, Inc.**
Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply because it’s the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences is able to consider what may be a small commercial success nothing less than a human triumph.

**BOOTH 401**

**Medical College of Wisconsin**
The Clinical Immunodiagnostic and Research Laboratory (CIRL) and Allergy Immunology Diagnostic Lab Center (AIDLC), at MCW, perform comprehensive testing for the diagnosis of primary immunodeficiencies (PIDs) and allergic disorders. The CIRL performs flow cytometric-based assays for the detection of PIDs. The AIDLC performs serologic assays for the diagnosis of hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis and latex allergy. The AIDLC also performs a Salmonella Typhi IgG assay to quantitate specific antibody responses to the killed polysaccharide S. typhi vaccine.

**BOOTH 101**

**National Jewish Health**
National Jewish Health Advanced Diagnostic Laboratories is a CAP, CLIA and CAP15189SM laboratory with unparalleled expertise developing immunological tests for immune deficiency and immune dysregulation - including comprehensive analysis of the complement system as well as the innate and adaptive immune systems, beryllium exposure, evaluation of hypersensitivity to nickel, cobalt and chromium metals in the context of joint implant failure, testing for infectious disease and molecular diagnostic tests. We have decades of experience in diagnostic testing in respiratory disease, immune deficiency, allergy and autoimmunity. Through collaborations with our world-renowned physicians and laboratory scientists, we develop high-quality laboratory tests and new therapies that transform lives.

**BOOTH 301**

**Novartis**
Novartis Pharmaceuticals Corporation is dedicated to discovering, developing, manufacturing and marketing prescription drugs that help meet our customers’ medical needs and improve their quality of life. For more information please visit our exhibit.

**NOT EXHIBITING**

**Seattle Children’s Research Institute**
Ranked as one of the top five children’s hospitals by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho. Seattle Children’s Research Institute is internationally recognized for its work in immunology and gene therapy through its Program in Cell and Gene Therapy (PCGT). The PCGT is developing curative therapies for children with inherited diseases of the blood and immune system. It is actively implementing gene replacement clinical trials and, in parallel, developing novel gene editing approaches for these disorders and for restoring tolerance in autoimmunity and transplantation. More information: www.seattlechildrens.org/research

**BOOTH 406**

**Shire – Commercial**
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

**BOOTH 103**

**Shire – Medical Affairs**
The Shire Medical Affairs booth will be staffed by Shire Medical Affairs representatives who are able to answer medical and scientific questions about Shire’s immune globulin products. For more information on the Immunology therapeutic area, please visit www.shire.com
<table>
<thead>
<tr>
<th>Poster</th>
<th>Poster Title</th>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A NOVEL MUTATION IN THE SAND DOMAIN OF AIRE EXPLAINS THE HIDDEN RISK IN A PATIENT WITH TYPE I DIABETES MELLITUS</td>
<td>Jordan K. Abbott</td>
<td>National Jewish Health</td>
</tr>
<tr>
<td>2</td>
<td>MYELOSUPPRESSION EFFECT OF TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS IN PRIMARY IMMUNE DEFICIENCY DISEASE PATIENTS</td>
<td>Mehdi Adeli</td>
<td>Hamad Medical Corporation</td>
</tr>
<tr>
<td>3</td>
<td>NOVEL FAMILIAL NK CELL IMMUNODEFIENCY REVEALED BY MASS CYTOMETRY AND WHOLE EXOME SEQUENCING</td>
<td>Joshua Alinger</td>
<td>Washington University in St Louis</td>
</tr>
<tr>
<td>4</td>
<td>COMPOUND HETEROZYGOUS RTEL1 MUTATIONS IN A CHILD WITH NEUTROPIA, LYMPHADENITIS, RECURRENT INFECTIONS, AND DECREASED NK CELL FUNCTION.</td>
<td>Aba Al-Kaabi</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>5</td>
<td>CLINICAL, IMMUNOLOGICAL AND MOLECULAR CHARACTERIZATION OF 93 PATIENTS WITH MAJOR HISTOCOMPATIBILITY CLASS II DEFICIENCY: A SINGLE CENTRE EXPERIENCE</td>
<td>Hamoud Al-Mousa</td>
<td>King Faisal Specialist Hospital &amp; Research Center</td>
</tr>
<tr>
<td>6</td>
<td>A RARE CASE OF IDIOPATHIC CD4 LYMPHOCYTOPENIA WITH ACUTE RESPIRATORY FAILURE</td>
<td>Afia Babar</td>
<td>The Wright Center for Graduate Medical Education</td>
</tr>
<tr>
<td>7</td>
<td>RETROSPECTIVE ANALYSIS OF THE IMPORTANCE OF IMMUNOLOGIC EVALUATION IN PATIENTS RECEIVING RITUXIMAB AND CLINICAL IMPLICATIONS</td>
<td>Sara Barmettler</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>8</td>
<td>FUNCTIONAL DIAGNOSIS OF ATAXIA TELANGIECTASIA IN A FEMALE INFANT IDENTIFIED VIA NEWBORN SCREENING FOR SCID (NBS SCID)</td>
<td>Sara Barmettler</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>9</td>
<td>IDENTIFICATION OF T-CELL RECEPTOR CLONOTYPES IMPORTANT IN THE PATHOGENESIS OF COMMON VARIABLE IMMUNODEFIENCY (CVID)</td>
<td>Sara Barmettler</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>10</td>
<td>T CELL LYMPHOPENIA WITH JAK3 MUTATIONS ASSOCIATED WITH DECREASED SIGNALING THROUGH THE IL-7 RECEPTOR</td>
<td>Jenna R.E. Bergerson</td>
<td>Ann and Robert H. Lurie Children's Hospital of Chicago</td>
</tr>
<tr>
<td>11</td>
<td>TREATMENT SATISFACTION DURING CLINICAL TRIALS WITH THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PATIENTS WITH PIDD IN EUROPE (EU) AND NORTH AMERICA (NA) WHO WERE PREVIOUSLY TREATED WITH IVIG</td>
<td>Todd Berner</td>
<td>Shire</td>
</tr>
<tr>
<td>12</td>
<td>TREATMENT PREFERENCE ON THE NEW SUBCUTANEOUS IMMUNOGLOBULIN 20% (SCIG 20%) TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFIENCY DISEASES (PIDD) IN EUROPE (EU)</td>
<td>Todd Berner</td>
<td>Shire</td>
</tr>
<tr>
<td>13</td>
<td>COMPLEX IMMUNE COMPLEXES – A RARE CASE OF XLA AND MPGN</td>
<td>Annaliesse Blincoe</td>
<td>CHU Sainte-Justine, University of Montreal</td>
</tr>
<tr>
<td>14</td>
<td>INCREASED MEMORY B CELLS – AN UNEXPECTED FINDING IN A PATIENT WITH A SPLICE SITE MUTATION IN PIK3R1 RESPONSIBLE FOR HYPER-IgM SYNDROME</td>
<td>Annaliesse Blincoe</td>
<td>CHU Sainte-Justine, University of Montreal</td>
</tr>
<tr>
<td>15</td>
<td>A NEW CASE OF X-LINKED PIGMENTARY RETICULATE DISORDER LINKED TO A RECURRENT MUTATION IN POLA1</td>
<td>Arturo Borzutzky</td>
<td>Pontificia Universidad Católica de Chile</td>
</tr>
<tr>
<td>16</td>
<td>PRIMARY INTESTINAL LYMPHANGIECTASIA (WALDMANN’S DISEASE) MIMICKING COMMON VARIABLE IMMUNODEFIENCY</td>
<td>Arturo Borzutzky</td>
<td>Pontificia Universidad Católica de Chile</td>
</tr>
<tr>
<td>17</td>
<td>CHRONIC MUCOCUTANEOUS CANDIDIASIS DUE TO LIFR DEFICIENCY (STÜVE-WIEDEMANN SYNDROME)</td>
<td>Arturo Borzutzky</td>
<td>Pontificia Universidad Católica de Chile</td>
</tr>
<tr>
<td>18</td>
<td>Th17 IMPAIRMENT IN A PATIENT WITH ACTIVATED PHOSPHOINOSITIDE-3-KINASE-Δ SYNDROME (APSD) AND SALMONELLA SEPSIS.</td>
<td>Giorgia Bucciol</td>
<td>University of Padova; KU Leuven</td>
</tr>
<tr>
<td>19</td>
<td>RECURRENT SEVERE RESPIRATORY INFECTIONS DUE TO PATHOGENIC VARIANT IN TECPR2</td>
<td>Roxanne C. Oriel</td>
<td>Hofstra Northwell School of Medicine</td>
</tr>
<tr>
<td>Poster</td>
<td>Poster Title</td>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>20</td>
<td>CVID WITH RENAL INTERSTITIAL INFLAMMATORY INFILTRATE OF CD3+ CD8+ T CELLS</td>
<td>Jason W Caldwell</td>
<td>Wake Forest University School of Medicine</td>
</tr>
<tr>
<td>21</td>
<td>16q24 DUPLICATION AND IVEMARK SYNDROME: A NOVEL GENOMIC CAUSE?</td>
<td>Magda Carneiro-Sampaio</td>
<td>University of Sao Paulo</td>
</tr>
<tr>
<td>22</td>
<td>HYPERCOAGULABLE STATE IN CHRONIC GRANULOMATOUS DISEASE (CGD)</td>
<td>Johana B Castro-Wagner</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>23</td>
<td>SEVERE COMBINED IMMUNE DEFICIENCY (SCID): NEED FOR UNIVERSAL NEWBORN SCREENING (NBS) IN PENNSYLVANIA (PA)</td>
<td>Hey Chong</td>
<td>Children's Hospital of Pittsburgh</td>
</tr>
<tr>
<td>24</td>
<td>A NOVEL CAUSE OF LYMPHOPENIA AND PRIMARY IMMUNODEFICIENCY ASSOCIATED WITH GERMLINE-ENCODED LOSS-OF-FUNCTION VARIANTS IN SGPL1</td>
<td>Megan A. Cooper</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td>25</td>
<td>MHV68 INFECTION IN A NOVEL rag2F62L/F62L MOUSE MODEL BASED ON A PATIENT WITH CID-AI/G PHENOTYPE</td>
<td>Krisztian Csomas</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>26</td>
<td>SAFETY AND EFFECTIVENESS OF CONTINUOUS PROPHYLAXIS WITH AZITHROMYCIN FOR AUTOSOMAL DOMINANT HYPER-IgE SYNDROME (AD-HIES) PATIENTS: A 5-YEARS FOLLOW-UP</td>
<td>Jose Marcos Cunha</td>
<td>Federal University of Rio de Janeiro</td>
</tr>
<tr>
<td>27</td>
<td>A NOVEL MUTATION IN RIT1 GENE CAUSING NOONAN SYNDROME TYPE 8: MANAGEMENT OF HYPOGAMMAGLOBULINEMIA AND SEVERE ANEMIA ASSOCIATED WITH EXTENSIVE GASTROINTESTINAL LYMPHANGIECTASIA</td>
<td>Jose Marcos Cunha</td>
<td>Federal University of Rio de Janeiro</td>
</tr>
<tr>
<td>28</td>
<td>COMBINED IMMUNODEFICIENCY IN A BOY WITH MILLER-DIEKER SYNDROME.</td>
<td>Yesim Demirdag</td>
<td>Columbia University Medical Center, New York Presbyterian Hospital</td>
</tr>
<tr>
<td>29</td>
<td>ANTI-POLYSACCHARIDE ANTIBODIES AGAINST PNEUMOCOCCAL SEROTYPES IN PATIENTS WITH RECURRENT INFECTIONS</td>
<td>Victoria R Dimitriades</td>
<td>University of California Davis Medical Center</td>
</tr>
<tr>
<td>30</td>
<td>GLILD (GRANULOMATOUS LYMPHOCYTIC INTERSTITIAL LUNG DISEASE) TREATMENT IN A PEDIATRIC PATIENT WITH CTLA4 DEFICIENCY: CASE REPORT</td>
<td>Mayra Dorna</td>
<td>Universidade de Sao Paulo</td>
</tr>
<tr>
<td>31</td>
<td>INITIATION OF 20% SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY NAIVE TO IG THERAPY</td>
<td>Carla Duff</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>32</td>
<td>IMMUNOMODULATORY EFFECTS OF RAPAMYCIN IN XENOGENEIC GRAFT VERSUS HOST DISEASE</td>
<td>Grégory Ehx</td>
<td>University of Liege</td>
</tr>
<tr>
<td>33</td>
<td>BROADENING OUR UNDERSTANDING OF THE NONINFECTIOUS DISEASE COMPLICATIONS OF CVID WITHIN THE UNITED STATES.</td>
<td>Jocelyn Farmer</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>34</td>
<td>SHIFTING OF INTRAVENOUS GAMMAGLOBULIN REPLACEMENT TO SUBCUTANEOUS ROUTE: A NEW APPROACH IN BRAZIL.</td>
<td>Natasha R Ferraroni</td>
<td>UniCEUB</td>
</tr>
<tr>
<td>35</td>
<td>EXPLORING THE CLINICAL AND IMMUNOLOGICAL DIFFERENCES BETWEEN COMMON VARIABLE IMMUNODEFICIENCY (CVID) AND IgG DEFICIENCY</td>
<td>Charles A. Filion</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>36</td>
<td>HYPER IgD SYNDROME (HIDS) PRESENTING AS ARTHRITIS WITHOUT FEVER</td>
<td>Joel Louis Gallagher</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>37</td>
<td>PREVALENCE AND TREATMENT OF MONOGENIC CAUSES OF GRANULOMATOUS AND LYMPHOCYTIC INTERSTITIAL LUNG DISEASE (GLILD) IN PATIENTS PREVIOUSLY DIAGNOSED WITH CVID</td>
<td>Joel Louis Gallagher</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>38</td>
<td>SEVERE AUTO-IMMUNE ENTEROPATHY IN A PATIENT WITH A LOSS OF FUNCTION MUTATION IN TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3 (TNFAIP3/A20)</td>
<td>Yael Gernez</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>39</td>
<td>VARIABLE PRESENTATION OF CHROMOSOMAL INSTABILITY SYNDROMES</td>
<td>Mirinda Gillespie</td>
<td>Johns Hopkins All Children's Hospital</td>
</tr>
<tr>
<td>Poster</td>
<td>Poster Title</td>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>RAPIDLY EROSIVE ARTHRITIS IN IPEX SYNDROME AFTER BONE MARROW TRANSPORT</td>
<td>Miriah C Gillispie</td>
<td>Baylor College of Medicine/Texas Children's Hospital</td>
</tr>
<tr>
<td>41</td>
<td>THE DISTINCT PHENOTYPE AND FUNCTION OF CONVENTIONAL NK CELLS IN THE PERIPHERAL BLOOD AND TERMINAL ILEUM OF CROHN'S DISEASE PATIENTS</td>
<td>Sarah Glover</td>
<td>University of Florida</td>
</tr>
<tr>
<td>42</td>
<td>SUCCESSFUL TREATMENT OF MULTIPLE BRAIN ABSCESSES CAUSED BY TRICHOSPORON INKIN IN A PATIENT WITH X-LINKED CHRONIC GRANULOMATOUS DISEASE (CGD)</td>
<td>Joud Hajjar</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>43</td>
<td>REPORT OF A NOVEL FOXP3 VARIANT ASSOCIATED WITH RENAL FAILURE AND IMMUNE DYSREGULATION</td>
<td>Gretchen Harmon</td>
<td>Thomas Jefferson University Hospital &amp; Nemours A.I. duPONT Hospital for Children</td>
</tr>
<tr>
<td>44</td>
<td>FAMILIAL ALPS WITH VARIABLE PRESENTATIONS</td>
<td>Donna S. Hummell</td>
<td>Vanderbilt University (Vanderbilt Children's Hospital)</td>
</tr>
<tr>
<td>45</td>
<td>VARIABILITY OF PRIMARY IMMUNODEFICIENCY AND PROGRESSION TO CVID: A CASE REPORT</td>
<td>Tracy A Hwangpo</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>46</td>
<td>PERSISTENT HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH RITUXIMAB AND BORTEZOMIB FOR AUTOIMMUNE HEMOLYTIC ANEMIA</td>
<td>Melissa Iammatteo</td>
<td>Montefiore Medical Center/Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>47</td>
<td>DIAGNOSTIC RATES OF GENETIC PANELS IN A LARGE SCID COHORT</td>
<td>Jane Juusola</td>
<td>GeneDx</td>
</tr>
<tr>
<td>48</td>
<td>HYPOGAMMAGLOBULINEMIA AFTER RITUXIMAB TREATMENT IN PEDIATRIC PATIENTS WITH AUTOIMMUNE CNS DISEASES</td>
<td>Amer M Khojah</td>
<td>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</td>
</tr>
<tr>
<td>49</td>
<td>AUTOSOMAL-RECESSIVE STAT-3-LIKE HYPER-IgE SYNDROME CAUSED BY A HOMOZYGOUS MUTATION IN A ZINC FINGER TRANSCRIPTION FACTOR</td>
<td>Sara Sebnem Klic</td>
<td>Uludag University</td>
</tr>
<tr>
<td>50</td>
<td>A NEW LIQUID 10% INTRAVENOUS IMMUNOGLOBULIN (IVIG) ADMINISTERED WITH 15-MINUTE TITRATION PERIODS ALLOWS SHORTER INFUSION DURATIONS AND TOLERABILITY SIMILAR TO A 5% FORMULATION</td>
<td>Gary I. Kleiner</td>
<td>University of Miami Miller School of Medicine</td>
</tr>
<tr>
<td>51</td>
<td>NEWBORN SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) IN GEORGIA: FALSE POSITIVES ON REPEAT TESTING</td>
<td>Lisa Kobrynski</td>
<td>Emory University</td>
</tr>
<tr>
<td>52</td>
<td>THE USE OF PIOGLITAZONE AS THERAPEUTIC APPROACH IN CHRONIC GRANULOMATOUS DISEASE: A SINGLE CASE EXPERIENCE</td>
<td>Patroula Koletsi</td>
<td>Great Ormond Street Hospital</td>
</tr>
<tr>
<td>53</td>
<td>ITRACONAZOLE PROPHYLAXIS THERAPEUTIC DRUG MONITORING (TDM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)</td>
<td>Patroula Koletsi</td>
<td>Great Ormond Street Hospital</td>
</tr>
<tr>
<td>54</td>
<td>IMPORTANCE OF GENETIC CONFIRMATION IN THE DIAGNOSIS OF CHRONIC GRANULOMATOUS DISEASE</td>
<td>Samantha A Kreuzburg</td>
<td>NIAID/NIH</td>
</tr>
<tr>
<td>55</td>
<td>ANALYSIS OF NCF1 IN PATIENTS WITH p47phox DEFICIENT CHRONIC GRANULOMATOUS DISEASE (CGD) AND NORMAL SUBJECTS BY DROPLET DIGITAL PCR (DDPCR)</td>
<td>Douglas B. Kuhns</td>
<td>NCI-Frederick</td>
</tr>
<tr>
<td>56</td>
<td>PROTEIN LOSING ENTEROPATHY IS A RISK FACTOR FOR INFECTIONS REQUIRING HOSPITALIZATION IN PATIENTS WITH FONTA</td>
<td>Sarah Kogan Nicholas</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>57</td>
<td>ELIMINATING NON-PATHOGENIC VARIATIONS FROM HUMAN EXOMES USING BLACKLISTS</td>
<td>Patrick Maffucci</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>58</td>
<td>REFRACTORY AUTOIMMUNE CYTOPENIA LINKED TO VARICELLA INFECTION IN A CHILD WITH RAG DEFICIENCY</td>
<td>Aniko Eva Malik</td>
<td>Department of Pediatrics Semmelweis University</td>
</tr>
<tr>
<td>Poster</td>
<td>Poster Title</td>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>59</td>
<td>POOR IMMUNE RECONSTITUTION FOLLOWING MATCHED SIBLING HEMATOPOIETIC STEM CELL TRANSPANTATION (HSCT) FOR X-LINKED LYMPHOPROLIFERATIVE DISORDER (XLP): SHOULD WE RECONSIDER MATCHED CARRIER SIBLINGS AS HSCT DONORS IN X-LINKED IMMUNE DEFICIENCY?</td>
<td>Anu Mallapaty</td>
<td>Children’s Healthcare of Atlanta, Emory University School of Medicine</td>
</tr>
<tr>
<td>60</td>
<td>A NOVEL DOMINANT NEGATIVE IKZF1 MUTATION C476A&gt;G (N159S) LEADS TO A COMBINED IMMUNE DEFICIENCY WITH ABSENT B CELLS AND ABNORMAL T CELL MATURATION AND FUNCTION</td>
<td>Rebecca Marsh</td>
<td>Cincinnati Children’s Hospital Medical Center</td>
</tr>
<tr>
<td>61</td>
<td>AIRE AND IL-7 RECEPTOR COMPOUND HETEROZYGOUS MUTATIONS RESULTING IN A NOVEL PRESENTATION OF AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY (APECED)</td>
<td>Rushita Mehta</td>
<td>Montefiore Medical Center</td>
</tr>
<tr>
<td>62</td>
<td>CLINICAL FEATURES AND TREATMENT RESPONSES OF AUTOIMMUNE CYTOPENIAS WITH PRIMARY IMMUNODEFICIENCY AT A TERTIARY PEDIATRIC CARE FACILITY</td>
<td>Anna K. Meyer</td>
<td>Johns Hopkins All Children’s Hospital</td>
</tr>
<tr>
<td>63</td>
<td>SEVERE VIRAL INFECTIONS: DO NOT FORGET ADENOSINE DEAMINASE 2 DEFICIENCY (DADA2).</td>
<td>Isabelle Meyts</td>
<td>University Hospitals Leuven</td>
</tr>
<tr>
<td>64</td>
<td>ALPS AND GAUCHER DISEASE. A CLINICAL AND BIOCHEMICAL OVERLAP</td>
<td>Maurizio Miano</td>
<td>IRCCS Istituto Giannina Gaslini</td>
</tr>
<tr>
<td>65</td>
<td>SINGLE/MULTI-LINEAGE BONE MARROW FAILURES SECONDARY TO PIDs-RELATED KNOWN/NOVEL MUTATIONS. A SINGLE CENTER EXPERIENCE.</td>
<td>Maurizio Miano</td>
<td>IRCCS Istituto Giannina Gaslini</td>
</tr>
<tr>
<td>66</td>
<td>BONE MARROW FAILURE SECONDARY TO ADA2 DEFICIENCY IN ADULT SIBLINGS</td>
<td>Thomas F. Michniacki</td>
<td>University of Michigan, C.S. Mott Children’s Hospital</td>
</tr>
<tr>
<td>67</td>
<td>NOVEL MISSENSE MUTATION IN X-LINKED INHIBITOR OF APOPTOSIS (XIAP) LEADING TO THE DEVELOPMENT OF GRANULOMATOUS INTERSTITIAL LUNG DISEASE (GLILD)</td>
<td>Ranjeet Minocha</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td>68</td>
<td>A CASE OF UNEXPLAINED MONTHLY FEVERS</td>
<td>Roshni Naik</td>
<td>SUNY Downstate Medical Center</td>
</tr>
<tr>
<td>69</td>
<td>NEW INSIGHTS FROM TRANSCRIPTOMIC ANALYSIS OF INTERFERON-GAMMA TREATED LEUKOCYTES FROM CHRONIC GRANULOMATOUS DISEASE AND INTERFERON-GAMMA RECEPTOR DEFICIENCY PATIENTS</td>
<td>Antonio Condino-Neto</td>
<td>University of Sao Paulo</td>
</tr>
<tr>
<td>70</td>
<td>EVALUATION OF THE OUTCOMES OF PROPHYLACTIC ANTIBIOTICS AND IMMUNOGLOBULIN REPLACEMENT IN PATIENTS WITH SPECIFIC ANTIBODY DEFICIENCY</td>
<td>An Nguyen</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>71</td>
<td>INTRAVENOUS IMMUNOGLOBULIN-RELATED HEMOLYSIS IN KAWASAKI DISEASE: CASE REPORT AND REVIEW OF LITERATURE</td>
<td>Rofida Nofal</td>
<td>St. John Providence Children’s Hospital</td>
</tr>
<tr>
<td>72</td>
<td>IDENTIFYING PREDICTORS OF PRIMARY IMMUNODEFICIENCY (PID) IN INFLAMMATORY BOWEL DISEASE (IBD)</td>
<td>Mei-Sing Ong</td>
<td>Harvard Medical School, Boston Children’s Hospital</td>
</tr>
<tr>
<td>73</td>
<td>THE CHANGING FACE OF COMPLETE DIGEORGE ANOMALY: ATHYMIC PATIENTS WITH CHARGE SYNDROME</td>
<td>Grace Toledo Padron</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>74</td>
<td>EFFICACY, SAFETY, AND TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) DURING THE NORTH AMERICAN (NA) PHASE 2/3 STUDY</td>
<td>Kenneth Paris</td>
<td>LSU Health Sciences Center</td>
</tr>
<tr>
<td>Poster</td>
<td>Poster Title</td>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>75</td>
<td>SAFETY/TOLERABILITY OF THE NEW HUMAN SUBCUTANEOUS IMMUNOGLOBULIN (SCIG 20%) IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)</td>
<td>Kenneth Paris</td>
<td>LSU Health Sciences Center</td>
</tr>
<tr>
<td>76</td>
<td>COMMON ANTIGEN ANTIBODY MEASUREMENTS FOR ASSESSMENT OF HUMORAL IMMUNITY</td>
<td>Antony Parker</td>
<td>The Binding Site Group Ltd.</td>
</tr>
<tr>
<td>77</td>
<td>THE RESPONSE TO TYPHI VI VACCINATION IS COMPROMISED IN INDIVIDUALS WITH ANTIBODY DEFICIENCY</td>
<td>Antony Parker</td>
<td>The Binding Site Group Ltd.</td>
</tr>
<tr>
<td>78</td>
<td>EVOLUTION OF IMMUNODEFICIENCY IN A PATIENT WITH KABUKI SYNDROME.</td>
<td>Bhumika Patel</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>79</td>
<td>IMMUNODEFICIENCY IN MIRAGE SYNDROME</td>
<td>Jay P. Patel</td>
<td>Seattle Children's Hospital</td>
</tr>
<tr>
<td>80</td>
<td>CD40/CD40L PATHWAY IS ASSOCIATED WITH INCREASED NEUTROPHIL EXTRACELLULAR TRAPS RELEASE IN BEHÇET’S DISEASE</td>
<td>Sandro Felix Perazzio</td>
<td>Federal University of Sao Paulo, University of Washington and Center for Immunity and Immunotherapies/Seattle Children's Research Institute</td>
</tr>
<tr>
<td>81</td>
<td>CD40/CD40L PATHWAY PLAYS A ROLE IN INCREASED NEUTROPHIL ACTIVATION IN BEHÇET’S DISEASE</td>
<td>Sandro Felix Perazzio</td>
<td>Federal University of Sao Paulo, University of Washington and Center for Immunity and Immunotherapies/Seattle Children's Research Institute</td>
</tr>
<tr>
<td>82</td>
<td>GRANULOMATOUS INTERSTITIAL LUNG DISEASE IN COMMON VARIABLE IMMUNODEFICIENCY: A CASE SERIES OF PATIENTS TREATED WITH RITUXIMAB AS A SINGLE AGENT</td>
<td>Deena Pourang</td>
<td>Kaiser Permanente Los Angeles Medical Center</td>
</tr>
<tr>
<td>83</td>
<td>THE EVALUATION OF THE HEALTH-RELATED QUALITY OF LIFE USING THE CVID_QOL SURVEY IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY: IMPACT OF CLINICAL, IMMUNOLOGICAL AND THERAPY-RELATED FACTORS ON THE BURDEN OF DISEASE</td>
<td>Federica Pulvirenti</td>
<td>Sapienza, University of Rome</td>
</tr>
<tr>
<td>84</td>
<td>AN UNUSUAL PRESENTATION OF A RARE COMBINED IMMUNODEFICIENCY</td>
<td>Andrea A. Ramirez</td>
<td>Baylor College of Medicine / Texas Children’s Hospital</td>
</tr>
<tr>
<td>85</td>
<td>IMMUNE DYSREGULATION IN WEST NILE VIRUS ENCEPHALITIS CAUSING OPSOCLONUS-MYOCLONUS SYNDROME (OMS)</td>
<td>Erin Wahle Rasmussen</td>
<td>University of Iowa Hospitals and Clinics</td>
</tr>
<tr>
<td>86</td>
<td>SELECTIVE IgA DEFICIENCY (SlsAd): AN UPDATE ON THE CLINICAL AND IMMUNOLOGICAL CHARACTERIZATION OF A COHORT OF COLOMBIAN PATIENTS.</td>
<td>Jose Luis Franco Restrepo</td>
<td>Universidad de Antioquia</td>
</tr>
<tr>
<td>87</td>
<td>A GLOBAL NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) OF HYQVIA IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)</td>
<td>Arye Rubenstein</td>
<td>Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>88</td>
<td>CVID MASQUERADING AS LYMPHOMA: TWO CASE REPORTS</td>
<td>Tamar N. Rubin</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>89</td>
<td>X-LINKED AGAMMAGLOBULINEMIA (XLA) DIAGNOSED IN VIETNAMESE TEENAGER WHO PRESENTED WITH GASTROINTESTINAL DISEASE AND FOUND TO HAVE A NOVEL BRUTON’S TYROSINE KINASE (BTK) GENE MUTATION</td>
<td>Tamar N. Rubin</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>90</td>
<td>PRESENCE OF IMMUNE DEFICIENCY INCREASES THE RISK OF HOSPITALIZATION IN PATIENTS WITH NOROVIRUS INFECTION</td>
<td>Keith Sacco</td>
<td>Mayo Clinic Jacksonville</td>
</tr>
<tr>
<td>91</td>
<td>CORD BLOOD TRANSPLANTATION DOES NOT AMELIORATE MEVALONATE KINASE DEFICIENCY PHENOTYPE DESPITE FULL ENGRAFTMENT: A CASE REPORT</td>
<td>Blachy J Dávila Saldaña</td>
<td>Children’s National Medical Center</td>
</tr>
<tr>
<td>Poster</td>
<td>Poster Title</td>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>92</td>
<td>CRYPTOCOCCAL SEPSIS AS INITIAL PRESENTATION OF CD40L DEFICIENCY</td>
<td>Blachy J Dávila Saldaña</td>
<td>Children’s National Medical Center</td>
</tr>
<tr>
<td>93</td>
<td>CLINICAL SPECTRUM OF A BRAZILIAN COHORT OF ACTIVATED PHOSPHOINOSITIDE 3-</td>
<td>Gesmar Segundo</td>
<td>Seattle Children’s Institute Research</td>
</tr>
<tr>
<td></td>
<td>KINASE Δ SYNDROME TYPE 1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>ORAL, PERIANAL AND COLONIC ULCERS: AN UNUSUAL PRESENTATION IN AN INFANT</td>
<td>Gesmar Segundo</td>
<td>Seattle Children’s Institute Research</td>
</tr>
<tr>
<td></td>
<td>WITH A NOVEL Mutation IN THE WAS GENE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>FOLLOW UP DURING 6 YEARS OF 48 PATIENTS WITH SUBCUTANEOUS IMMUNOGLOBULIN</td>
<td>Analía Gisela Seminario</td>
<td>Ricardo Gutiérrez Children’s Hospital</td>
</tr>
<tr>
<td></td>
<td>TREATMENT BY PUSH AS REPLACEMENT AND IMMUNOMODULATORY THERAPY.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>NEW CHALLENGES IN AGAMMAGLOBULINEMIC PATIENTS WITH ENTEROVIRUS</td>
<td>Analía Gisela Seminario</td>
<td>Ricardo Gutiérrez Children’s Hospital</td>
</tr>
<tr>
<td>97</td>
<td>A CASE SERIES: CLUES TO A DIAGNOSIS OF CHRONIC GRANULOMATOUS DISEASE</td>
<td>Shanmuganathan Chandrakasan</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>IN PATIENTS PRESENTING WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>A CLINICOPATHOLOGICAL STUDY OF COMMON VARIABLE IMMUNE DEFICIENCY (CVID)</td>
<td>Tukisa D. Smith</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td></td>
<td>PATIENTS MISDIAGNOSED WITH LYMPHOMA.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>CEREBELLAR DEGENERATION IN A PATIENT WITH IPEX SYNDROME</td>
<td>Ariane Soldatos</td>
<td>National Institute of Neurological Disorders</td>
</tr>
<tr>
<td></td>
<td>and Stroke</td>
<td></td>
<td>and Stroke</td>
</tr>
<tr>
<td>100</td>
<td>CLASS SWITCH MEMORY B CELLS ARE LOW IN 30% OF PATIENTS WITH RECURRENT</td>
<td>Ricardo Sorensen</td>
<td>Louisiana State University Health Sciences</td>
</tr>
<tr>
<td></td>
<td>INFECTIONS BUT NOT IN HEALTHY CONTROLS.</td>
<td></td>
<td>Center</td>
</tr>
<tr>
<td>101</td>
<td>THROMBOCYTOPENIA AS INITIAL PRESENTATION OF IKAROS DEFICIENCY</td>
<td>Panida S Siaroon</td>
<td>Johns Hopkins All Children’s Hospital;</td>
</tr>
<tr>
<td></td>
<td>ASSOCIATED WITH A NOVEL IKZF1 MUTATION</td>
<td></td>
<td>University of South Florida Morsani College of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medicine</td>
</tr>
<tr>
<td>102</td>
<td>SAFETY AND TOLERABILITY DURING CLINICAL TRIALS OF THE NEW SUBCUTANEOUS</td>
<td>Daniel Suez</td>
<td>Allergy, Asthma &amp; Immunology Clinic</td>
</tr>
<tr>
<td></td>
<td>IMMUNOGLOBULIN 20% FORMULATION (SCIG 20%) IN PATIENTS WITH PIDD IN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EUROPE AND NORTH AMERICA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>LEUKOCLASTIC VASCULITIS IN COMPLEMENT DEFICIENCY TEMPORARILY</td>
<td>Sara E Sussman</td>
<td>LSUHSC-New Orleans</td>
</tr>
<tr>
<td></td>
<td>ASSOCIATED WITH INTRAVENOUS GAMMAGLOBULIN THERAPY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>IKBA GAIN-OF-FUNCTION MUTATION IN A FEMALE PRESENTING WITH</td>
<td>Cristina Swanson</td>
<td>University of Washington and Seattle Children’s</td>
</tr>
<tr>
<td></td>
<td>INFECTIONS AND HYPER IgM, BUT WITHOUT ECTODERMAL DYSPLASIA.</td>
<td></td>
<td>Hospital</td>
</tr>
<tr>
<td>105</td>
<td>MULTIPLE INTESTINAL ATRESIA WITH COMBINED IMMUNODEFICIENCY</td>
<td>Bahar Torabi</td>
<td>Research Institute of McGill University Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Centre</td>
</tr>
<tr>
<td>106</td>
<td>ANALYSES OF PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)</td>
<td>Richard L. Wasserman</td>
<td>Dallas Allergy</td>
</tr>
<tr>
<td></td>
<td>TREATED BY DIFFERENT MODES OF ADMINISTRATION OF IMMUNOGLOBULIN (IG)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>THERAPY DURING THREE CONSECUTIVE STUDIES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>EVALUATION OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS (PK) OF</td>
<td>Richard L. Wasserman</td>
<td>Dallas Allergy</td>
</tr>
<tr>
<td></td>
<td>GAMMAPLEX® 10% VERSUS GAMMAPLEX® 5% IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DISEASES (PID)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>PARTIAL RAG DEFICIENCY IN A CHILD WITH AUTOIMMUNE CYTOPENIA AND FEATURES</td>
<td>Emma Westermann - Clark</td>
<td>University of South Florida Morsani College of</td>
</tr>
<tr>
<td></td>
<td>OF AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS)</td>
<td></td>
<td>Medicine</td>
</tr>
</tbody>
</table>
### POSTER LISTING

<table>
<thead>
<tr>
<th>Poster</th>
<th>Poster Title</th>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>109</td>
<td>POPULATION PHARMACOKINETIC (PK) MODELING AND SIMULATION OF VARIOUS DOSING INTERVALS AND DETERMINATION OF THE DOSE ADJUSTMENT FACTOR AFTER SC ADMINISTRATION OF IMMUNOGLOBULIN 20% (SCIG 20%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)</td>
<td>Leman Yel</td>
<td>Shire</td>
</tr>
<tr>
<td>110</td>
<td>COMMON VARIABLE IMMUNODEFICIENCY (CVID) IN ADULTS: SINGLE-CENTER FIRST YEAR EXPERIENCE IN CALI, COLOMBIA.</td>
<td>Andres F Zea-Vera</td>
<td>Universidad del Valle</td>
</tr>
<tr>
<td>111</td>
<td>IDENTIFICATION OF GENETIC SUSCEPTIBILITY VARIANTS FOR SEVERE VIRAL RESPIRATORY INFECTIONS IN CHILDREN</td>
<td>Yu Zhang</td>
<td>National Institute of Allergy and Infectious Diseases, National Institutes of Health</td>
</tr>
<tr>
<td>112</td>
<td>A NOVEL CASE OF A PATIENT WITH CYSTIC FIBROSIS AND OMENN SYNDROME</td>
<td>Jessica Zibert</td>
<td>University of Kansas Department of Allergy/Immunology</td>
</tr>
<tr>
<td>113</td>
<td>INTERIM RESULTS OF A NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF SCIG 10% INFUSION FACILITATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHUPH20) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)</td>
<td>Brent Bialik</td>
<td>Shire</td>
</tr>
<tr>
<td>114</td>
<td>LOW T CELL RECEPTOR EXCISION CIRCLES (TREC) ON ROUTINE NEWBORN SCREENING (NBS) LEADING TO AN EARLY DIAGNOSIS OF PROPERDIN DEFICIENCY CARRIAGE</td>
<td>Yasmin Hamzavi Abedi</td>
<td>Hofstra Northwell School of Medicine</td>
</tr>
</tbody>
</table>

### SPONSORS

**THANK YOU TO OUR SUPPORTERS!**

**PREMIUM**
- Shire
- Grifols

**PLATINUM**
- CSL Behring
- Horizon Pharma

**GOLD**
- ADMA Biologics

**SILVER**
- Immune Deficiency Foundation
- USIDNET

**BRONZE**
- Celgene
- Coram CVS Specialty Infusion Services
- Jeffrey Modell Foundation
- Leadiant Biosciences, Inc.
- Robert A. Good Society
- Seattle Children’s Research Institute
2017 CIS School in Primary Immunodeficiency Diseases
GALVESTON, TEXAS • OCTOBER 19-22, 2017

Calling all Fellows
Submit an application today